'Nano-immunotherapy' halts glioblastoma in mice

Brain
Glioblastoma is the most common brain tumor in adults but is difficult to treat because of challenges getting drugs across the blood-brain barrier. (VSRao / Pixabay)

One of the most difficult challenges in treating the brain cancer glioblastoma is that few drugs can pass through the blood-brain barrier. Scientists at Cedars-Sinai in Los Angeles have developed a system to circumvent this hurdle—one that combines a powerful immuno-oncology drug with a polymer-based delivery vehicle that can cross the blood-brain barrier.

The researchers showed that this “nano-immunotherapy” treatment crossed the blood-brain barrier in mouse models of glioblastoma, and that it stopped tumor cells from multiplying. They published their findings in the journal Nature Communications.

The Cedars-Sinai team used the polymer scaffold to deliver two types of immune checkpoint inhibitors, blocking either CTLA-4 or PD-1. When injected into the bloodstream of mice, the drugs quickly infiltrated brain tumors, but not healthy brain tissue, the researchers reported.  

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

RELATED: Treating glioblastoma with a Ziopharm drug and IL-12 gene therapy

Brain tumors are normally able to suppress immune attacks using macrophages and T regulatory cells (Tregs). The Cedars-Sinai researchers observed that after they treated the mice with nano-immunotherapy, the checkpoint inhibitors blocked Tregs and macrophages. That allowed tumor-killing immune cells to flood in and treat the tumors.

Glioblastoma multiforme is the most common type of brain tumor in adults, accounting for 17% of all brain cancer diagnoses, according to the American Association of Neurological Surgeons. It’s a notoriously difficult tumor to treat, not only because of the challenge of getting drugs past the blood-brain barrier, but also because the cancer tends to spread rapidly and the brain has a limited ability to heal itself.

Several research groups are looking for workarounds in treating glioblastoma. Earlier this month, scientists from Brigham and Women’s Hospital and the Dana-Farber Cancer Institute announced promising early results from a phase 1 study of a gene-therapy approach that incorporates Ziopharm’s oral drug veledimex. And the Ivy Brain Tumor Center is testing combos that include Karyopharm Therapeutics’ recently approved Xpovio, a nuclear-export inhibitor.

Cedars-Sinai’s Julia Ljubimova, M.D., Ph.D., professor of neurosurgery and lead author of the new study, says further preclinical work will need to be done before the nano-immunotherapy approach can be tried in patients with glioblastoma. But she remains optimistic.

"The horizon for treatment of brain cancer is getting clearer," Ljubimova said in a statement. "We hope that by delivering multifunctional new-generation drugs through the blood-brain barrier, we can explore new therapies for many neurological conditions."

Suggested Articles

Vaccinex is developing a drug it hopes could be the first disease-modifying treatment for Huntington disease, but that program hit a snag in phase 2.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.